I-BET151 (GSK1210151A)

Catalog No.S2780

I-BET151 (GSK1210151A) Chemical Structure

Molecular Weight(MW): 415.44

I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 170 In stock
USD 270 In stock
USD 870 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

1 Customer Review

  • OVTOKO and OVCA420 cells were treated with DMSO, JQ1 (1 μM) or I-BET151 (1 μM). Cell lysates were immunoblotted with indicated antibodies.

    Theranostics, 2016, 6(2):219-30.. I-BET151 (GSK1210151A) purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM in cell-free assays, respectively.
Features Optimized to retain excellent BET target potency and selectivity while enhancing the in vivo pharmacokinetics and terminal half-life to enable prolonged in vivo studies.
Targets
BRD3 [1]
(Cell-free assay)
BRD2 [1]
(Cell-free assay)
BRD4 [1]
(Cell-free assay)
0.25 μM 0.5 μM 0.79 μM
In vitro

I-BET151 exhibits potent selectivity over an extensive range of diverse protein types such as COX-2, P450, Aurora B, GSK3β, PI3K-γ, GPCR, ion channels, and transporters. Similar to I-BET762 (GSK525762A), I-BET151 displays potent binding affinity to BRD2, BRD3 and BRD4 with KD of 0.02-0.1 μM, and significantly inhibits lipopolysaccharide-stimulated IL-6 cytokine production in human peripheral blood mononuclear cells (PBMC) and whole blood (WB) as well as rat WB with IC50 of 0.16 μM, 1.26 μM, and 1.26 μM, respectively. I-BET151 (0.5 or 5 μM) inhibits the binding of BETs (BRD2, BRD3, BRD4, and BRD9) but not the binding of 23 other bromodomain proteins in HL60 nuclear extract to acetylated histone peptides. I-BET151 has potent efficacy against cell lines harboring different MLL-fusions such as MV4;11, RS4;11, MOLM13, and NOMO1 cells with IC50 of 15-192 nM. Consistently, I-BET151 completely ablates the colony-forming potential of MLL-fusion-driven leukaemias (MOLM13) but not leukaemias driven by tyrosine kinase activation (K562). I-BET151 also displays potent efficacy in both liquid culture and clonogenic assays using primary murine progenitors transformed with either MLL-ENL or MLL-AF9. I-BET151 treatment significantly induces apoptosis and prominent G0/G1 arrest in MLL-fusion cell lines driven by distinct MLL fusions (MOLM13 and MV4;11 containing MLL-AF9 and MLL-AF4, respectively) but not the K562 cells, probably due to the inhibition of transcription of BCL2, C-MYC and CDK6 by blocking the recruitment of BRD3/4, PAFc and SEC components into transcriptional start site (TSS). [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV4;11 NHjoUpRkgXSxdH;4bYNqfHliYYPzZZk> Mn3TglExOCEQvF2= MWXEUXNQ MVXJR|UxRTJ4IH7N M{TPdVIyQTZ2M{Sw
RS4;11 NF3F[29kgXSxdH;4bYNqfHliYYPzZZk> NEDzbHN,OTByIN88US=> NX61S3J{TE2VTx?= NISzTJhKSzVyPUG5NkBvVQ>? NX\4e|JkOjF7NkSzOFA>
MOLM13 M4D1dIN6fG:2b4jpZ4l1gSCjc4PhfS=> MnS0glExOCEQvF2= MkTnSG1UVw>? M1PRZ2lEPTB;MUKwJI5O NFLFelIzOTl4NEO0NC=>
NOMO1 M2i1[YN6fG:2b4jpZ4l1gSCjc4PhfS=> NXX5OHo3hjFyMDFOwG0> MmjQSG1UVw>? MXnJR|UxRTF3IH7N MWOyNVk3PDN2MB?=
HEL NFHu[XNkgXSxdH;4bYNqfHliYYPzZZk> NUHjNpJzhjFyMDFOwG0> MkLDSG1UVw>? NYKzPJVRUUN3ME2xJO69VQ>? MYiyNVk3PDN2MB?=
K562 M{X4XYN6fG:2b4jpZ4l1gSCjc4PhfS=> NXTJPG5JhjFyMDFOwG0> MkjoSG1UVw>? NVvoT4dPUUN3ME6xNFAh|ryP M3vmcVIyQTZ2M{Sw
MEG01 MXjjfZRwfG:6aXPpeJkh[XO|YYm= NGrNVYl,OTByIN88US=> NFjRRo9FVVOR NWm0[JZTUUN3ME2yOUDPxE1? MYGyNVk3PDN2MB?=
HL60 NFPvWXpkgXSxdH;4bYNqfHliYYPzZZk> NHS5Z|l,OTByIN88US=> NFjafZBFVVOR MnjITWM2OD16OUCgcm0> MofGNlE6PjR|NEC=
MV4;11 MUjBdI9xfG:|aYOgZZN{[Xl? M33XUp4yODBizszN MmixSG1UVw>? MVfpcoR2[2W|IHHwc5B1d3Orcx?= M3rMdVIyQTZ2M{Sw
MOLM13 MYTBdI9xfG:|aYOgZZN{[Xl? Mlr4glExOCEQvF2= M1\FW2ROW09? M2jkN4lv\HWlZYOgZZBweHSxc3nz MnOwNlE6PjR|NEC=
MV4;11 NUfDUotnTnWwY4Tpc44h[XO|YYm= MW\EUXNQ M2nZRYRm[3KnYYPld{B1cGVicnXjdpVqfG2nboSgc4YhSlKGMz:0JIFv\CCrbYDhbZJm\CC{ZXPyeYl1dWWwdDDv[kBETEt7IHHu[EBRSUZzIITvJJRp\SC2cnHud4NzcXC2aX;uZYwhe3SjcoSgd4l1\Q>? Mnv6NlE6PjR|NEC=
PBMC MYXGeY5kfGmxbjDhd5NigQ>? NYfvRmdGTE2VTx?= MX;pcohq[mm2czDJUE03KHerdHigdGlEPTBib3[gOk44 M1f4OFIzPDN5MUG1
A2 MlfOSpVv[3Srb36gZZN{[Xl? Mo\1glExKM7:TR?= MVzEUXNQ NY\jN20zemWjY4TpeoF1\XNibHH0[Y51KEiLVj2x NHrFOFAzOzJ3NUKxPC=>
A72 M4PnV2Z2dmO2aX;uJIF{e2G7 NXzERpA{hjFyIN88US=> NIHyeHRFVVOR M4DMfZJm[WO2aY\heIV{KGyjdHXueEBJUVZvMR?= NHvPcowzOzJ3NUKxPC=>
BC1 NVvwbYdoT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MlW5glEh|ryP MmW3SG1UVw>? MoTaTWM2OD1{MkCgcm0> NFy3[GozOzd7MkS0PC=>
BC3 M{fjW2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NITBbnp,OSEQvF2= MmXCSG1UVw>? M3zVVWlEPTB;NE[wJI5O NV;pfIJOOjN5OUK0OFg>
BCBL1 NEXRTpNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NHvSRVJ,OSEQvF2= NVnCS2kyTE2VTx?= MlLsTWM2OD1|M{Cgcm0> M1PhcVI{Pzl{NES4
BJAB MX3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NYDHTm8yhjFizszN NHLiTZdFVVOR M2PZbmlEPTB;OUewJI5O MXKyN|c6OjR2OB?=
Namalwa MXrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M2LaWZ4yKM7:TR?= NYiyS5dbTE2VTx?= NYq2XGFPUUN3ME25O|Ahdk1? NHX6RXozOzd7MkS0PC=>
Jurkat MX;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M1\BOJ4yKM7:TR?= MkC2SG1UVw>? MX;JR|UxRTF{MkCgcm0> M{HLOlI{Pzl{NES4
MM1S MkLpS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MkSwglEh|ryP NXjC[pp1TE2VTx?= Mkm3TWM2OD15NkCgcm0> NYfiN5ZUOjN5OUK0OFg>
U266 M1\xdGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MXT+NUDPxE1? M4G3TGROW09? NXnrfYJnUUN3ME25OVAhdk1? MmTINlM4QTJ2NEi=
UM-PEL-1 MYXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MVP+NUDPxE1? MlXNSG1UVw>? MUjJR|UxRTJzMDDuUS=> NGTyRmszOzd7MkS0PC=>
UM-PEL-3 NWjvSndCT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MoLWglEh|ryP NU\ycHU5TE2VTx?= NFGzVFJKSzVyPUG4NEBvVQ>? MkD3NlM4QTJ2NEi=
BC1 MoP1SpVv[3Srb36gZZN{[Xl? MXK1NFAhdk1? NHGwcoxFVVOR M4\BRYlv\HWlZYOgZ4VtdC2leXPs[UBienKnc4S= M17MRVI{Pzl{NES4
BC3 MnXRSpVv[3Srb36gZZN{[Xl? MUG1NFAhdk1? M2TCT2ROW09? M3vHUIlv\HWlZYOgZ4VtdC2leXPs[UBienKnc4S= MUWyN|c6OjR2OB?=
BC1 M2noS2Z2dmO2aX;uJIF{e2G7 Ml;TPFAxKG6P Mnj4SG1UVw>? M33lW5Jm\HWlZYOgZ{1OgWNicILveIVqdiCuZY\lcJM> M3Hzd|I{Pzl{NES4
BC3 MV;GeY5kfGmxbjDhd5NigQ>? MUG4NFAhdk1? NXXhSpdYTE2VTx?= NGjWT5lz\WS3Y3XzJIMuVXmlIIDyc5RmcW5ibHX2[Yx{ NV60So11OjN5OUK0OFg>
H929 NFnCeHhHfW6ldHnvckBie3OjeR?= M3\VZ54yKM7:TR?= NID3dIJFVVOR NVrlOpNNcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> NUTa[WsxOjR|M{W0PVk>
KMS12PE MmnZSpVv[3Srb36gZZN{[Xl? NEH3WFV,OSEQvF2= M1rRZ2ROW09? M4fYRYlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= MoPkNlQ{OzV2OUm=
KMS12BM MkPSSpVv[3Srb36gZZN{[Xl? NH\YcYZ,OSEQvF2= MlHPSG1UVw>? MUPpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 NUDt[4V1OjR|M{W0PVk>
KMS18 NFWyVJhHfW6ldHnvckBie3OjeR?= NV7lT45thjFizszN M3jzbGROW09? MVLpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 M4C0[|I1OzN3NEm5
KMS11 NUL1dYx1TnWwY4Tpc44h[XO|YYm= MoDkglEh|ryP MVzEUXNQ MUDpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 MUSyOFM{PTR7OR?=
RPMI8226 NULLTGkzTnWwY4Tpc44h[XO|YYm= NIDkdYZ,OSEQvF2= MUjEUXNQ MXvpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 NUDsNFE6OjR|M{W0PVk>
H929 NFT5b4tCeG:ydH;zbZMh[XO|YYm= NYnFenVIhjFizszN NILuNmRFVVOR NXzEd4JqcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NGDkeVQzPDN|NUS5PS=>
KMS12PE NVP2UoNlSXCxcITvd4l{KGG|c3H5 M2f4OJ4yKM7:TR?= M3jQN2ROW09? M4PlO4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NUjSU2c1OjR|M{W0PVk>
KMS12BM NGHHfXNCeG:ydH;zbZMh[XO|YYm= NFXGN4d,OSEQvF2= M{XNU2ROW09? NHjaOJJqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M1HjcFI1OzN3NEm5
KMS18 MVTBdI9xfG:|aYOgZZN{[Xl? NHe0OWN,OSEQvF2= MkLCSG1UVw>? Mnu1bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M4XGeFI1OzN3NEm5
KMS11 NH7pTI5CeG:ydH;zbZMh[XO|YYm= MVL+NUDPxE1? Mn;oSG1UVw>? M3P6c4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NVjCeY5GOjR|M{W0PVk>
RPMI8226 MYLBdI9xfG:|aYOgZZN{[Xl? MnHXglEh|ryP NHjhcpVFVVOR M36xZ4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M1fKd|I1OzN3NEm5
U87MG NFzpRWZHfW6ldHnvckBie3OjeR?= NH3OWo1,OTBizszN MYfEUXNQ NF;jZpNz\WS3Y3XzJHU5P02JIHPlcIx2dGG{IFHUVEB4cXSqIFnDOVAhd2ZiMT6wOUDPxE1? Mn33NlQ1QTZ|OEG=
A172 M4jsT2Z2dmO2aX;uJIF{e2G7 Mnq5glExKM7:TR?= M37nWWROW09? M2jkcZJm\HWlZYOgZ4VtdHWuYYKgRXRRKHerdHigTWM2OCCxZjCxMlI5KM7:TR?= NFrBWYMzPDR7NkO4NS=>
SW1783 NFnlXppHfW6ldHnvckBie3OjeR?= MofxglExKM7:TR?= NGPxS4xFVVOR NV7UXG42emWmdXPld{Bk\WyudXzhdkBCXFBid3n0bEBKSzVyIH;mJFIvPjhizszN M1HHcFI1PDl4M{ix
U87MG NFPPPFBHfW6ldHnvckBie3OjeR?= NFPFVJp,OTBizszN MXXEUXNQ NXq5UotxcW6lcnXhd4V{KHC{b4DvdpRqd25ib3[gZ4VtdHNiaX6geIhmKEdzL2OgeJJidnOrdHnvci=> MkDzNlQ1QTZ|OEG=
RAW267.4 M1zBXGZ2dmO2aX;uJIF{e2G7 NWDHNIZ{OSEQvF2= NF\2NoNFVVOR MWHy[YR2[2W|IFnMMVYheHKxZIXjeIlwdiCrbnT1Z4VlKGK7IFzQVy=> MXiyOFg2QTByOB?=
RAW267.4 M1rwS2Z2dmO2aX;uJIF{e2G7 MmfoNUDPxE1? M3\iSGROW09? NF76SVhz\WS3Y3XzJJRp\SCjc4PvZ4lifGmxbjDi[ZR4\WWwIFLSSFQh[W6mIHHj[ZR6dGG2ZXSgdFY2 NEDObo0zPDh3OUCwPC=>
Me007 M4jnOmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MUj+NVAxKM7:TR?= NIi2XGRFVVOR MVLpcohq[mm2czD0bIUh\3Kxd4To MYeyOFkxPjF|Nx?=
SK-Mel-28 MlT5S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MlnkglExOCEQvF2= NXr1T4piTE2VTx?= MmrCbY5pcWKrdIOgeIhmKGe{b4f0bC=> M1XRfFI1QTB4MUO3
Mel-RMU M4PNOGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MYH+NVAxKM7:TR?= MV3EUXNQ NGTobm1qdmirYnn0d{B1cGViZ4Lve5Rp M4PSdVI1QTB4MUO3
Mel-JD NHT5OplIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MmGwglExOCEQvF2= MX;EUXNQ NEj2O3pqdmirYnn0d{B1cGViZ4Lve5Rp MlXLNlQ6ODZzM{e=
Mel-RM MnzrS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NFTxZmV,OTByIN88US=> MlS4SG1UVw>? MYTpcohq[mm2czD0bIUh\3Kxd4To NYnsO3RmOjR7ME[xN|c>
Me007 MoLoRZBweHSxc3nzJIF{e2G7 NV3ZemxNhjFyMDFOwG0> MlTWSG1UVw>? MmD5bY5lfWOnczDhdI9xfG:|aYO= NWfEOmVuOjR7ME[xN|c>
SK-Mel-28 NEnSVJRCeG:ydH;zbZMh[XO|YYm= MmDQglExOCEQvF2= NGnFWmJFVVOR M{eyTYlv\HWlZYOgZZBweHSxc3nz M{PlNlI1QTB4MUO3
Mel-RMU NFfpRnlCeG:ydH;zbZMh[XO|YYm= Mlu3glExOCEQvF2= NYXk[m9oTE2VTx?= MoGxbY5lfWOnczDhdI9xfG:|aYO= NI\x[pQzPDlyNkGzOy=>
Mel-JD NVu2Wm9pSXCxcITvd4l{KGG|c3H5 NInafmF,OTByIN88US=> M4W3eWROW09? NFv0VoVqdmS3Y3XzJIFxd3C2b4Ppdy=> NV61cm9ZOjR7ME[xN|c>
Mel-RM NVH2N2FFSXCxcITvd4l{KGG|c3H5 MnjlglExOCEQvF2= NUHHXJRtTE2VTx?= M37UUIlv\HWlZYOgZZBweHSxc3nz NG\zWHYzPDlyNkGzOy=>
Me007 NHTvXppHfW6ldHnvckBie3OjeR?= M4LBVVExKM7:TR?= MVPEUXNQ NX;nT|BocW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBjgSC3cILl[5Vt[XSrb36gc4YheDJz M{HwZ|I1QTB4MUO3
SK-Mel-28 MkLLSpVv[3Srb36gZZN{[Xl? MoftNVAh|ryP M{KwNmROW09? MlnzbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDifUB2eHKnZ4XsZZRqd25ib3[gdFIy MmTDNlQ6ODZzM{e=
Mel-RMU MmPSSpVv[3Srb36gZZN{[Xl? NGnxPFkyOCEQvF2= NFLWTlhFVVOR MVPpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHL5JJVxemWpdXzheIlwdiCxZjDwNlE> M3zyd|I1QTB4MUO3
Mel-JD MV3GeY5kfGmxbjDhd5NigQ>? M2j1PFExKM7:TR?= M3G2RmROW09? MmjVbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDifUB2eHKnZ4XsZZRqd25ib3[gdFIy NIXSU24zPDlyNkGzOy=>
Mel-RM NV3SS5VoTnWwY4Tpc44h[XO|YYm= MkKzNVAh|ryP NWHBUGNUTE2VTx?= NWnnbIVVcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBjgSC3cILl[5Vt[XSrb36gc4YheDJz NVvrS5c1OjR7ME[xN|c>
Me007 NXnmN5MxTnWwY4Tpc44h[XO|YYm= MnzMNVAh|ryP MnrxSG1UVw>? NWDycItXfXC{ZXf1cIF1\XNicILvZZBweHSxdHnjJIFv\CClZXzsJIN6[2ynIHHydoV{fCCpZX7ldy=> NFXzbXQzPDlyNkGzOy=>
SK-Mel-28 NYXIcnN4TnWwY4Tpc44h[XO|YYm= NULXc3M1OTBizszN MYnEUXNQ NHnCXmx2eHKnZ4XsZZRmeyCycn;hdI9xfG:2aXOgZY5lKGOnbHygZ5lkdGViYYLy[ZN1KGenbnXz NXHjb3RpOjR7ME[xN|c>
Mel-RMU NWTmXWVWTnWwY4Tpc44h[XO|YYm= MnvTNVAh|ryP NUPQRVkzTE2VTx?= M1fJ[JVxemWpdXzheIV{KHC{b3Hwc5B1d3SrYzDhcoQh[2WubDDjfYNt\SCjcoLld5Qh\2WwZYO= NYj5XZhxOjR7ME[xN|c>
Mel-JD NUPSR4tOTnWwY4Tpc44h[XO|YYm= M3TMOFExKM7:TR?= MXPEUXNQ NFHafot2eHKnZ4XsZZRmeyCycn;hdI9xfG:2aXOgZY5lKGOnbHygZ5lkdGViYYLy[ZN1KGenbnXz Mk\DNlQ6ODZzM{e=
Mel-RM MUPGeY5kfGmxbjDhd5NigQ>? NGLPN3YyOCEQvF2= M2KxZ2ROW09? MX71dJJm\3WuYYTld{Bxem:jcH;weI91cWNiYX7kJINmdGxiY4njcIUh[XK{ZYP0JIdmdmW| NX:2dmw4OjR7ME[xN|c>

... Click to View More Cell Line Experimental Data

In vivo Administration of I-BET151 at 30 mg/kg/day significantly inhibits tumor growth of murine MLL-AF9 and human MLL-AF4 leukaemia in mice, and provides marked survival benefit. [1]

Protocol

Kinase Assay
+ Expand

Fluorescence anisotropy (FP) ligand displacement assay:

All components are dissolved in buffer of composition 50 mM HEPES pH 7.4, 150 mM NaCl and 0.5 mM CHAPS with final concentrations of BRD 2/3/4 75 nM, fluorescent ligand 5 nM. 10 μL of this reaction mixture is added using a micro multidrop to wells containing 100 nL of various concentrations of I-BET151 or DMSO vehicle (1% final) in Greiner 384 well Black low volume microtitre plate and equilibrated in the dark for 60 minutes at room temperature. Fluorescence anisotropy is read in Envision (lex = 485 nm, lEM = 530 nm; Dichroic = 505 nM).
Cell Research
+ Expand
  • Cell lines: MV4;11, MOLM13, NOMO1, RS4;11, HEL, HL60 and K562
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 24, or 72 hours
  • Method:

    Cells are exposed to various concentrations of I-BET151 for 24 or 72 hours in 384-well or 96-well plates. For cell growth inhibition assays, plates are added with CellTiter-Glo reagent using a volume equivalent to the cell culture volume in the wells, shaken for approximately 2 minutes and chemiluminescent signal is read on the Analyst GT or EnVision Plate Reader. For cell proliferation assays, CellTiter-Aqueous One is added to each well and plates are incubated for 4 hours at 37 °C. Absorbance is read at 490 nm on a SpectraMax Gemini reader


    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: NOD-SCID mice injected intravenously with MV4;11 cells, and C57BL/6 mice injected intravenously with MLL-AF9 cells
  • Formulation: Dissolved in normal saline containing 5% (v/v) DMSO and 10% (w/v) Kleptose HPB
  • Dosages: ~30 mg/kg/day
  • Administration: Intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 27 mg/mL (64.99 mM)
DMSO <1 mg/mL
Water <1 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 415.44
Formula

C23H21N5O3

CAS No. 1300031-49-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) supplier | purchase I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) cost | I-BET151 (GSK1210151A) manufacturer | order I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID